CTOs on the Move

Biofourmis

www.biofourmis.com

 
Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers. Biofourmis has built Biovitals™, a highly sophisticated personalized artificial intelligence (AI)-powered health analytics platform that predicts clinical exacerbation days in advance before a critical event. Biovitals™ is the backbone of the company`s Digital Therapeutics product pipeline, which spans ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Milan Shah
 Chief Technology Officer Profile
Jaydev Thakkar
 Chief Operating Officer Profile

Funding

Biofourmis raised $100M on 09/03/2020

Similar Companies

Pyxis Oncology

Founded by Longwood Fund, Pyxis Oncology is building a differentiated portfolio of biologics, including antibody-drug conjugates (ADCs) and immunotherapies, to improve the lives of patients with difficult-to-treat cancers. Pyxis is employing site-specific conjugation technology to develop highly stable ADCs with enhanced therapeutic indexes. Pyxis is also advancing a diverse portfolio of immunotherapies that target broad immune regulators as well as novel immune checkpoints identified through its immuno-oncology and cold tumor discovery efforts.

Synthekine

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments.

Molecular Pharmacology Limited (USA)

Molecular Pharmacology Limited (USA) is a West Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vitae Pharmaceuticals

Vitae Pharmaceuticals, Inc. focuses on discovering and developing drugs for various diseases. Its product candidates include VTP-34072, which is in a Phase II clinical trial for the treatment of type 2 diabetes; and VTP-37948 that is in Phase I clinical trials for alzheimer's disease. The company’s products in preclinical studies comprise VTP-43742 for the treatment of autoimmune disorders, such as psoriasis, multiple sclerosis, rheumatoid arthritis, Behcet's disease, and autoimmune uveitis; VTP-38443 for the treatment of acute coronary syndrome that consists of unstable angina and heart attacks; and VTP-38543 for the treatment of atopic dermatitis, an immune system mediated inflammation of the skin. Vitae Pharmaceuticals, Inc. has collaborations with Boehringer Ingelheim GmbH for the development of VTP-34072 and VTP-37948. Vitae Pharmaceuticals, Inc. was formerly known as Concurrent Pharmaceuticals, Inc. and changed its name to Vitae Pharmaceuticals, Inc. in January, 2005. The company was founded in 2001 and is headquartered in Fort Washington, Pennsylvania.

Medarray

Medarray is a Ann Arbor, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.